Affinity Asset Advisors’s Biogen BIIB Stock Holding History

Affinity Asset Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-40,000	Closed	-$11.4M	–	84
2023 Q2	$11.4M	Buy	+40,000	New	+$11.9M	3.98%	9

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Affinity Asset Advisors's BIIB Position: Q3 2023 in Review

Affinity Asset Advisors sold out of Biogen (BIIB) in Q3 2023, closing a stake of 40,000 shares — an estimated $11.4M sold.

Affinity Asset Advisors first reported a position in BIIB in Q2 2023 and held it in 1 quarter. The position peaked at $11.4M in Q2 2023. 965 funds tracked by Wall St. Rank hold BIIB as of Q3 2023.

Affinity Asset Advisors reported no remaining Biogen position as of Q3 2023 after selling out during the quarter.
Affinity Asset Advisors sold 40,000 Biogen shares in Q3 2023, an estimated $11.4M.
Affinity Asset Advisors first reported a position in Biogen in Q2 2023 and held it in 1 quarter.
Affinity Asset Advisors's Biogen position peaked at $11.4M in Q2 2023.
965 funds tracked by Wall St. Rank held Biogen as of Q3 2023.

Based on Affinity Asset Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.